A New Parameter Derived From DSA to Evaluate Cerebral Perfusion

August 31, 2023 updated by: Xi'an No.3 Hospital

The Association Between a New Parameter Derived From DSA and Outcomes in Cerebral Ischemia

This observational study focus on a new parameter of cerebral perfusion derived form digital substraction angiography.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Ischemic cerebrovascular disease is an important cause of death and disability in the world. Digital Subtraction Angiography (DSA) is the golden index for evaluating cerebral blood vessels. We introduced a new parameter derived from DSA to evaluate the perfusion to predict the outcomes in acute stroke with large vessel occlusion.

To study the possible relationship between the new parameter of cerebral perfusion derived from DSA and outcomes in cerebral ischemia（modified Rankin Scale）, we intend to retrospectively analyze the images derived from patients who undergone the DSA and follow-up outcomes（modified Rankin Scale）.

Study Type

Observational

Enrollment (Estimated)

30000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Tian Ye, doctor
  • Phone Number: +8613519131549
  • Email: chhty@sina.com

Study Locations

  • China
    • Shaanxi
      • Xi'an, Shaanxi, China, 710018

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

the study population is from primary care clinic

Description

Inclusion Criteria:

  1. Cerebral ischemia
  2. patients undergone DSA

Exclusion Criteria:

1.cerebral hemorrhage

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
good perfusion in DSA
We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(good perfusion)
middle perfusion in DSA
We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(middle perfusion)
poor perfusion in DSA
We introduced a new parameter derived from DSA to evaluate the perfusion in cerebral ischemia.(poor perfusion)

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the outcomes between good perfusions and poor perfusions
Time Frame: 3 months to 2 years
Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs).
3 months to 2 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
the outcomes between good perfusions and middle perfusions
Time Frame: 3 months to 2 years
Results are reported as odds ratios (ORs) with 95% confidence intervals (CIs).
3 months to 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Xi'an No.3 Hospital

Investigators

  • Study Director: Nannan Han, doctor, department of neurology Xi'an No3 Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 15, 2018

Primary Completion (Estimated)

July 15, 2028

Study Completion (Estimated)

July 15, 2038

Study Registration Dates

First Submitted

July 20, 2018

First Submitted That Met QC Criteria

July 20, 2018

First Posted (Actual)

July 31, 2018

Study Record Updates

Last Update Posted (Actual)

September 1, 2023

Last Update Submitted That Met QC Criteria

August 31, 2023

Last Verified

August 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Hnn

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cerebral Ischemia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe